Home › Critical Illness › NCT06223828
Azithromycin for Critical Asthma - Pediatrics
RecruitingPhase 2/3
Azithromycin as Immunomodulation Among Children Hospitalized for Critical Asthma: A Prospective, Open-Label, Non-Randomized, Interventional Study With Parallel Biospecimen Banking
Who can join
Ages 3 to 17 · All sexes
Full eligibility criteria
Inclusion criteria * Age 3-17 years * Admission to the PICU * Primary diagnosis of critical asthma * Prescription for continuous inhaled beta-agonist therapy and/or intravenous (IV) beta-agonist therapy * Prescription for intravenous systemic corticosteroids Exclusion criteria * Critical Congenital Heart Disease Unrepaired * Tracheostomy Dependence at Admission * Ongoing Exposure to Azithromycin or Macrolide Antibiotics for any indication * Past Medical History of Prolonged QT Syndrome or Arrhythmias * Concomitant respiratory pathology including Acute Chest Syndrome, Interstitial Lung Disease, Cystic Fibrosis, and pulmonary hypertension
About the study
The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.
What is being tested
- Azithromycin (drug)
Sponsor: Johns Hopkins All Children's Hospital · Participants: 100 · Started: Apr 2, 2024
Contact the study team
- Anthony A Sochet, MD · Phone: 727-487-3711
- Alexa R Roberts, MD · Phone: 602-526-4397
Official record on ClinicalTrials.gov — NCT06223828
Locations in the U.S.
| Florida | Johns Hopkins All Children's Hospital, St. Petersburg |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.